nach oben

Erschienen in:

01.12.2023 | Research

The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation

verfasst von: Sameh Gomaa, AnaMaria Lopez, Rachel Slamon, Rita Smith, Emmanuel Lapitan, Ginah Nightingale, Suzanne M. Miller, Kuang-Yi Wen

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Adjuvant endocrine therapy (AET) is pivotal for hormone receptor-positive breast cancer patients, significantly enhancing survival rates. Yet, adherence to AET remains challenging due to side effects. This study delves into the lived experience of breast cancer survivors concerning AET-induced side effects and examines differences in symptom profiles between Tamoxifen and aromatase inhibitors (AIs).

Methods

We interviewed 35 breast cancer survivors on AET, conducting qualitative iterative analysis using grounded theory. A codebook was developed to aid data coding and interpretation. NVIVO software facilitated comprehensive transcript analysis.

Results

Survivors reported a spectrum of side effects like hot flashes, sexual issues, joint pain, stiffness, mood swings, and fertility concerns. Symptom profiles differed based on AET type. Tamoxifen users experienced more frequent sexual side effects and mood swings, while AIs were linked to joint pain, stiffness, and bone health worries. Those on AET for over 6 months expressed heightened concerns about side effects.

Conclusion

Tailored patient education, aligned with AET type, empowers survivors to manage side effects using self-regulatory strategies. Acknowledging distinct symptom profiles enables informed decisions, improving adherence and quality of life.

Implications

This study underscores tailored survivorship support, equipping patients with tools to manage side effects, enhancing adherence, and long-term outcomes. The findings inform the integration of comprehensive survivorship programs, emphasizing individualized strategies for managing side effects and promoting better adherence and improved quality of life.

Bashar MA, Begam N (2022) Breast cancer surpasses lung cancer as the most commonly diagnosed cancer worldwide. Indian J Cancer 59(3):438–439PubMed

Arnold M et al (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66:15–23CrossRefPubMedPubMedCentral

Giaquinto AN et al (2022) Breast cancer statistics, 2022. CA: A Cancer J Clin 72(6):524–541

Berry DA et al (2005) Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. N Engl J Med 353(17):1784–1792CrossRefPubMed

Howell A et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62CrossRefPubMed

Davies C et al (2011) Early Breast Cancer Trialists′ Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–84CrossRefPubMed

Early Breast Cancer Trialists' Collaborative G (1998) Tamoxifen for early breast cancer : an overview of the randomized trials. Lancet 351: p. 1451–1467

Burstein HJ et al (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol 28(23):3784–3796

Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478CrossRefPubMedPubMedCentral

10.

Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606CrossRefPubMed

11.

Partridge AH et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556–562CrossRefPubMed

12.

Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59(1):97–102CrossRefPubMed

13.

Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322–328CrossRefPubMed

14.

Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220CrossRefPubMed

15.

Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439CrossRefPubMed

16.

Güth U et al (2011) Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work? Breast Cancer Res Treat 129(3):799–807CrossRefPubMed

17.

Cella D, Fallowfield LJ, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107(2):167–180CrossRefPubMed

18.

Pellegrini I et al (2010) Women’s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view. Psychooncology 19(5):472–479CrossRefPubMed

19.

Henry NL et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol : Off J Am Soc Clin Oncol 30(9):936–942CrossRef

20.

Kirk MC, Hudis CA (2008) Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast Cancer. Clin Breast Cancer 8(2):155–161CrossRefPubMed

21.

Wen K-Y, Smith R, Padmanabhan A, Goldstein L (2017) Patient experience of taking adjuvant endocrine therapy for breast cancer: a tough pill to swallow. Patient Experience J 4(3):104–114CrossRef

22.

Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145(2):525–534CrossRefPubMed

23.

Neugut A et al (2012) Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat 134(1):419–428CrossRefPubMedPubMedCentral

24.

Rani NS, Abd Wahab MS, Zulkifly HH, SH (2021) Mohamad, Factors associated with disease progression among hormone receptor-positive breast cancer patients treated with endocrine therapy: A 5-year cross-sectional, retrospective follow-up study. J Appl Pharm Sci 11(1): p. 072–077

25.

Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138(1):325–328CrossRefPubMed

26.

Sood N et al (2022) Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer. JAMA Netw Open 5(8):e2225345–e2225345CrossRefPubMedPubMedCentral

27.

Strauss A. Corbin JM, Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. 1998: SAGE Publications

28.

Beckwée D, Leysen L, Meuwis K, Adriaenssens N (2017) Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer 25:1673–1686CrossRefPubMed

29.

Din OS, Dodwell D, Wakefield RJ, Coleman RE (2010) Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat 120:525–538CrossRefPubMed

30.

Kligman L, Younus J (2010) Management of hot flashes in women with breast cancer. Curr Oncol 17(1):81–86CrossRefPubMedPubMedCentral

31.

Baumgart J et al (2013) Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20(2):162–168CrossRefPubMed

32.

Helland T et al (2019) Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Res Treat 177(1):185–195CrossRefPubMed

33.

van Laar M et al (2012) Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J 6:320–330CrossRefPubMedPubMedCentral

34.

Price R et al (2022) Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology 98(1):31–43CrossRefPubMed

35.

Browall M, Mijwel S, Rundqvist H, Wengström Y (2018) Physical activity during and after adjuvant treatment for breast cancer: an integrative review of women’s experiences. Integr Cancer Ther 17(1):16–30CrossRefPubMed

36.

Rogers LQ et al (2023) Physical activity intervention benefits persist months post-intervention: Randomized trial in breast cancer survivors. J Cancer Survivorship p. 1–13

37.

Galantino ML et al (2012) Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor–associated arthralgias. Integr Cancer Ther 11(4):313–320CrossRefPubMed

38.

Stout NL et al (2021) A systematic review of rehabilitation and exercise recommendations in oncology guidelines. CA Cancer J Clin 71(2):149–175CrossRefPubMed

Titel: The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation
verfasst von: Sameh Gomaa
AnaMaria Lopez
Rachel Slamon
Rita Smith
Emmanuel Lapitan
Ginah Nightingale
Suzanne M. Miller
Kuang-Yi Wen
Publikationsdatum: 01.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 12/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-023-08170-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation